Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA

Banys-Paluchowski, Malgorzata; Fehm, Tanja; Grimm-Glang, Donata; Rody, Achim; Krawczyk, Natalia

doi:10.1159/000520561

Cited by 14 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies in metastatic breast cancer established that the presence of CTCs reflects tumor burden and is prognostic for survival . Patients can be stratified into high-risk and low-risk cohorts based on their CTC blood concentration levels.…”

Section: Liquid Biopsy For Advanced-stage Diseasementioning

confidence: 99%

Applications of Liquid Biopsy for Surgical Patients With Cancer

Mahuron,

Fong

2024

JAMA Surg

View full text Add to dashboard Cite

ImportanceLiquid biopsy is an emerging tool with the potential to change oncologic care practices. Optimal clinical applications for its use are currently undefined for surgical patients.ObservationsLiquid biopsy analytes such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been the most clinically studied assays and were initially limited to advanced-stage disease. In the metastatic setting, CTCs and ctDNA levels are prognostic. Although their levels correlate with treatment response, CTC-guided systemic regimen switches for nonresponders have not been shown to improve clinical outcomes. ctDNA genomic profiling has succeeded, and there are now multiple plasma-based assays approved by the US Food and Drug Administration that can detect actionable mutations to guide systemic therapy. Technological advancements in assay sensitivity have expanded the use of ctDNA to early-stage and resectable disease, allowing for detection of minimal residual disease. Postoperative ctDNA levels are a strong predictor of disease recurrence, and ctDNA detection often precedes serum carcinoembryonic antigen elevation and radiographic changes. However, its use for surveillance has not been shown to improve clinical outcomes. A promising application of ctDNA is for adjuvant therapy escalation and de-escalation. A phase 2 clinical trial demonstrated that treatment de-escalation for patients with high-risk stage II colorectal cancer and negative postoperative ctDNA had similar recurrence-free survival as patients receiving standard-of-care chemotherapy. These results suggest that ctDNA may help select patients who will benefit from adjuvant chemotherapy, and multiple clinical trials are actively underway.Conclusions and RelevanceAlthough uncertainties regarding the optimal use of liquid biopsy remain, it has the potential to significantly improve care for patients with cancer at all stages of disease. It is critical that surgeons understand how to use and interpret these assays, and they should be active participants in clinical trials to advance the field.

show abstract

Section: Liquid Biopsy For Advanced-stage Diseasementioning

confidence: 99%

Applications of Liquid Biopsy for Surgical Patients With Cancer

Mahuron,

Fong

2024

JAMA Surg

View full text Add to dashboard Cite

show abstract

“…CirCe01 trial (NCT01349842) was another study investigating CTC-based therapy monitoring. Here the suggested early chemotherapy changes in patients without CTC response culminated in a longer median OS and PFS [ 58 ].…”

Section: Where Are We Nowmentioning

confidence: 99%

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going

et al. 2023

View full text Add to dashboard Cite

Liquid biopsy (LB) is an emerging diagnostic tool that analyzes biomarkers in the blood (and possibly in other body fluids) to provide information about tumor genetics and response to therapy. This review article provides an overview of LB applications in human cancer with a focus on breast cancer patients. LB methods include circulating tumor cells and cell-free tumor products, such as circulating tumor DNA. LB has shown potential in detecting cancer at an early stage, monitoring tumor progression and recurrence, and predicting patient response to therapy. Several studies have demonstrated its clinical utility in breast cancer patients. However, there are limitations to LB, including the lack of standardized assays and the need for further validation. Future potential applications of LB include identifying the minimal residual disease, early detection of recurrence, and monitoring treatment response in various cancer types. LB represents a promising non-invasive diagnostic tool with potential applications in breast cancer diagnosis, treatment, and management. Further research is necessary to fully understand its clinical utility and overcome its current limitations.

show abstract

“…Compared with solid biopsy, LB is a more comprehensive diagnostic test that uses blood, urine ( 67 ), saliva, and other biological fluids ( 68 , 69 ). After the sampling circulating tumor nucleic acids and cells are extracted and further analyzed ( 68 , 70 ). The major tumor component that is usually extracted for the identification of tumor characteristics is circulating tumor cells (CTCs) ( 71 ).…”

Section: Liquid Biopsy In Breast Cancermentioning

confidence: 99%

Potential utility of miRNAs for liquid biopsy in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) remains the most prevalent malignancy due to its incidence rate, recurrence, and metastasis in women. Conventional strategies of cancer detection– mammography and tissue biopsy lack the capacity to detect the complete cancer genomic landscape. Besides, they often give false- positive or negative results. The presence of this and other disadvantages such as invasiveness, high-cost, and side effects necessitates developing new strategies to overcome the BC burden. Liquid biopsy (LB) has been brought to the fore owing to its early detection, screening, prognosis, simplicity of the technique, and efficient monitoring. Remarkably, microRNAs (miRNAs)– gene expression regulators seem to play a major role as biomarkers detected in the samples of LB. Particularly, miR-21 and miR-155 among other possible candidates seem to serve as favorable biomarkers in the diagnosis and prognosis of BC. Hence, this review will assess the potential utility of miRNAs as biomarkers and will highlight certain promising candidates for the LB approach in the diagnosis and management of BC that may optimize the patient outcome.

show abstract

Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA

Cited by 14 publications

References 33 publications

Applications of Liquid Biopsy for Surgical Patients With Cancer

Applications of Liquid Biopsy for Surgical Patients With Cancer

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going

Potential utility of miRNAs for liquid biopsy in breast cancer

Contact Info

Product

Resources

About